NAMUR, Belgium--(BUSINESS WIRE)--Cardiatis S.A., developer and marketer of innovative minimally invasive treatments for thoracoabdominal aortic aneurysms, announced today that two sessions of rapid-fire clinical presentations will be devoted to highlighting the use of its aortic flow modulation technology as minimally invasive endovascular solution for the repair of thoracoabdominal aneurysms. A presentation will be dedicated to discussing three-year outcomes of the Strato study which proved superiority of Cardiatis technology to open surgical repair.
The 2014 VEITH Symposium will be held at New York Midtown Hilton between Tuesday November 18th and Saturday November 22nd and will feature over 900 presentations in more than 100 sessions throughout the five-day event.
The two sessions of presentations discussing Cardiatis Multilayer aortic Flow Modulator (MFM®) device will be held on the afternoon of Wednesday November 19th and the afternoon of Thursday November 20th:
- Session 31, which will start Wednesday at 2:13 pm, will feature presentations from the following distinguished speakers: Edward B. Diethrich, MD, Sherif Sultan, MD, Claude D. Vaislic, MD , Ralf R. Kolvenbach, MD, Daniel Benitti, MD, Erno Remsey-Semmelweis, MD, Maria Antonella Ruffino, MD, etc. The session will be moderated by both Frank J. Veith, MD and Edward B. Diethrich, MD.
- Session 53, which will start Thursday at 2:30 pm, will feature presentations from the following distinguished speakers: Amira Benjelloun, MD, Mark F. Fillinger, MD and Sherif Sultan, MD. The session will be moderated by both Timur P. Sarac, MD and Ali F. AbuRahma, MD.
In a separate presentation that will be held on the afternoon of Friday 21st Cardiatis executives will showcase the company’s platform market opportunities in terms of objectives and strategy, and will offer a glimpse of their in-development bifurcated device for the minimally invasive treatment of Crawford Extent IV thoracoabdominal aortic aneurysms.
Cardiatis is a commercial stage medical technology company with the target to become the leading provider of minimally invasive disease modifying solutions to patients with thoracoabdominal aneurysms. This represents a Gold Market for MFM® with $1 billion opportunity in this No-Man’s Land.